TWiV 951: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses Influenza incidence and vaccine effectiveness during the southern hemisphere influenza season in Chile, Nirsevimab for prevention of RSV infection in healthy late-preterm and term infants, severe Monkeypox in hospitalized patients, reinfections with different SARS-CoV-2 Omicron subvariants, impact of community masking on COVID-19 in Bangladesh, unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses, antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot, immunogenicity of bivalent mRNA vaccine boosters, long-term gastrointestinal sequelae following COVID-19, evaluation of an automated text message–based program to reduce use of acute health care resources after hospital discharge, and how in adults with COVID-19, melatonin was assessed for effects on inflammatory markers, clinical signs and symptoms, and mortality.

Click arrow to play
Download TWiV 951 (30 MB .mp3, 50 min)
Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Show notes at

1 thought on “TWiV 951: Clinical update with Dr. Daniel Griffin”

  1. If the covid-19 alpha vaccine is as good as the b.4 or b.5 boosters, is there any risk from these boosters..had 4 shots so far? There is always a risk, but anything substantial?

Comments are closed.

Scroll to Top